Summit Global Investments Buys New Position in Health Catalyst, Inc. (NASDAQ:HCAT)

Summit Global Investments bought a new stake in Health Catalyst, Inc. (NASDAQ:HCAT) during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 26,739 shares of the company’s stock, valued at approximately $121,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of HCAT. Group One Trading LLC increased its position in shares of Health Catalyst by 107.6% during the 4th quarter. Group One Trading LLC now owns 4,360 shares of the company’s stock worth $31,000 after purchasing an additional 2,260 shares during the last quarter. Two Sigma Securities LLC increased its position in shares of Health Catalyst by 19.5% during the 4th quarter. Two Sigma Securities LLC now owns 17,510 shares of the company’s stock worth $124,000 after purchasing an additional 2,862 shares during the last quarter. Legato Capital Management LLC increased its position in shares of Health Catalyst by 3.7% during the 4th quarter. Legato Capital Management LLC now owns 87,992 shares of the company’s stock worth $622,000 after purchasing an additional 3,171 shares during the last quarter. Quantbot Technologies LP acquired a new position in shares of Health Catalyst during the 4th quarter worth approximately $29,000. Finally, Price T Rowe Associates Inc. MD increased its position in shares of Health Catalyst by 8.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 62,443 shares of the company’s stock worth $442,000 after purchasing an additional 4,798 shares during the last quarter. Institutional investors and hedge funds own 85.00% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on HCAT. Canaccord Genuity Group lowered their price target on Health Catalyst from $10.00 to $9.00 and set a “buy” rating on the stock in a research report on Thursday, May 8th. KeyCorp decreased their target price on Health Catalyst from $7.00 to $5.00 and set an “overweight” rating on the stock in a report on Wednesday, April 16th. Royal Bank of Canada decreased their target price on Health Catalyst from $7.00 to $6.00 and set a “sector perform” rating on the stock in a report on Thursday, February 27th. Citigroup decreased their target price on Health Catalyst from $7.00 to $6.50 and set a “buy” rating on the stock in a report on Friday, April 25th. Finally, Stephens decreased their target price on Health Catalyst from $7.00 to $5.00 and set an “equal weight” rating on the stock in a report on Thursday, March 6th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.00.

Insider Activity at Health Catalyst

In related news, General Counsel Benjamin Landry sold 13,827 shares of the business’s stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $4.55, for a total value of $62,912.85. Following the completion of the sale, the general counsel now directly owns 160,437 shares in the company, valued at $729,988.35. The trade was a 7.93% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Daniel Lesueur sold 16,902 shares of the company’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $4.52, for a total value of $76,397.04. Following the sale, the chief operating officer now owns 216,250 shares of the company’s stock, valued at approximately $977,450. The trade was a 7.25% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 41,147 shares of company stock worth $182,284 in the last ninety days. 2.50% of the stock is owned by company insiders.

Health Catalyst Stock Performance

HCAT opened at $3.78 on Monday. The business has a fifty day simple moving average of $4.00 and a 200 day simple moving average of $5.47. The company has a market capitalization of $263.09 million, a PE ratio of -2.80 and a beta of 1.56. Health Catalyst, Inc. has a 1 year low of $3.49 and a 1 year high of $9.24. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.